Latest Healthcare It News

Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.

Singular Health deepens US healthcare foothold with ongoing Triple-S contract talks, PNS licence expansion, and Miami-Dade educational rollout, supported by a solid $10.1 million cash reserve.

IMEXHS Limited posted a 21% revenue increase in Q2 FY26, driven by a landmark public tender in Mexico deploying its AI-powered Aquila+ radiology platform. The company’s proprietary AI agents are now operational in live environments, supporting its strategy to own the full radiology workflow.

4DMedical has secured a pivotal three-year contract with SimonMed Imaging to deploy its CT:VQ™ lung imaging technology across over 170 US outpatient centres, while FY26 revenue rose 23% to $7.2 million on record scan volumes and global expansion.

Decidr AI Industries accelerated its commercial growth with a 71% jump in annualised exit-rate revenue to $13.6 million and bolstered its cash position to $23.4 million following a $14.2 million equity raise.

Cann Group reported its second-ever quarterly operating cash inflow of $0.24 million in Q4 FY2026, edging closer to cash flow break-even. The company expanded exports to the UK and Germany, launched new products, and completed a leadership transition while redeeming convertible notes and securing additional credit.

EBR Systems advanced its wireless cardiac pacing rollout in Q2 2026, completing 46 implants and signing 17 new purchasing contracts while shifting focus to deeper utilisation within existing accounts.

Unith Ltd boosted its AI digital human platform with ISO/IEC 27001:2022 certification, launched new SDKs, and secured $2.75 million in fresh capital to fuel growth and commercial expansion.

BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.

Rhythm Biosciences bolstered its financial position with a $5.2 million option underwriting while accelerating commercial adoption of its ColoSTAT® colorectal cancer test and advancing geneType™ partnerships internationally in Q4 FY26.

Audeara Ltd posted record FY26 cash receipts of $4.2 million and unaudited revenue of $4.44 million, driven by progress in AI audio licensing, exclusive assistive listening deals, and a large-scale Auracast deployment across retirement villages.

PainChek lifted implemented ARR by 5.9% to $4.46 million and secured its first US commercial contracts under a major Sabra REIT agreement, boosting customer receipts 27% in the June quarter.